Objective: To evaluate the efficacy of Ginseng combined with conventional therapy for stable angina pectoris(SAP). Methods: From the Cochrane Library, Pubmed, Embase, Web of Science, CNKI(China National Knowledge Infrastructure), Wanfang Datebase, VIP(Chinese Scientific Journals Database), CBM(Chinese Biomedicine Database), we reviewed the clinical randomized controlled trial(RCT), after screening and assessing the risk of bias, used RevMan 5.3 and Stata 15.0 software to make the Meta-analysis. Results: Thirteen studies were included with 1176 cases, involving 606 cases in the experimental group and 570 in the control group. The results of Meta-analysis showed that Ginseng combined with conventional therapy significantly has obvious effect on clinical effective rate(RR=1.29, 95％CI[1.21, 1.36], P<0.00001); ECG effective rate(RR=1.35, 95％CI[1.22, 1.50], P<0.00001); number of angina attacks(MD=-1.77, 95％CI[-2.64, -0.91], P<0.00001); duration of angina pectoris(MD=-2.16, 95％CI[-2.54, -1.78], P<0.00001); nitroglycerin dosage(MD=-1.52, 95％CI[-1.81, -1.23], P<0.00001), and it is better than using conventional therapy alone. Conclusion: Ginseng combined with conventional therapy for SAP can significantly improve clinical effective rate and ECG effective rate, reduce the number of angina attacks, shorten the duration of angina pectoris, and reduce nitroglycerin dosage. The development of ginseng-related proprietary Chinese medicines has good prospects. But due to the quality of studies is medium and low, it still needs to be confirmed by conducting high-quality RCTs.